A Phase 3 interventional study of Fixed dose combination Dipyrone and Codeine and Dipyrone in Pain, Postoperative, sponsored by Brazilian Clinical Research Institute. Completed at 3 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Brazilian Clinical Research Institute · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Pain, Postoperative with a site in Brazil — 8 open to participants now, 8 under way, 1 of them phase 3. Pain, Postoperative · Brazil.
Among the 56 studies in Pain, Postoperative with a site in Brazil, this one has the largest enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 3, and was the 44th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →8 of the 56 studies in Pain, Postoperative with a site in Brazil are open now. Recruiting first, the newest first:
Federal University of Bahia · Sites in Brazil
Ages 18–59
Faculdade de Ciências Médicas de Minas Gerais · Sites in Brazil
Ages 18–80
Universidade Federal do Rio de Janeiro · Sites in Brazil
Ages 18–65
University of Sao Paulo · Sites in Brazil
Ages 13+
Hospital de Base · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 7 · Phase 4 20
First in 1999; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 491 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 53 interventional studies, 800 across the 3 observational. Of the 36 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 56 have an industry lead sponsor. The 10 most frequent:
Brazilian Clinical Research Institute is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Brazilian Clinical Research Institute has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
4 of the studies in Pain, Postoperative with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07633444Federal University of BahiaTransauricular Vagus Nerve Stimulation Frequencies for Postoperative Pain | 2026-11-30 |
| NCT07388953Faculdade de Ciências Médicas de Minas GeraisPeripheral Autonomic Block (BAP) Plus Transversus Abdominis Plane Block (TAP) for Postoperative Analgesia After Minimally Invasive Left-Sided Colorectal Resection (BAPTAP) | 2026-12-05 |
| NCT07431632University of Sao PauloIntraoperative Cryoanalgesia Versus Thoracic Epidural Block in MIRPE (Minimally Invasive Repair of Pectus Excavatum) | 2027-01 |
| NCT07794267Hospital de BaseRemote Assessment of Pain and Recovery Quality After Surgery Using a Digital Form: A Pilot Study | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Pain, Postoperative with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase III clinical trial, multicentre, superiority, randomized, open, parallel groups, with active control and use of postoperative oral medication (multiple doses of medication).
The main objective is to evaluate the effectiveness and safety of the association in relation to the isolated use of medicines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fixed dose combination Dipyrone and Codeine
Drug: Dipyrone
Drug: Codeine
Proportion of participants achieving at least 50% of maximum pain relief within 6 hours
Proportion of participants achieving at least 50% of maximum pain relief within 6 hours after first drug administration, through the assessment of total pain relief (TOTPAR) after first drug administration. TOTPAR is calculated from the result of the 5-point categorical pain relief scale (adapted PAR scale, with the 5 categories: 1-no relief, 2-mild relief, 3-moderate relief, 4-a lot of relief, and 5-complete relief). The PAR will be evaluated 30 minutes, 1 hour, 1 hour and 30 minutes, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours after drug administration, so that the TOTPAR can take into account the progress of pain relief at 8 different timepoints.
Time frame: 6 hours
Pain assessment by the visual analogic scale score
The average visual analogic scale score (visual analogic scale from 0 to 10 cm, where 0 = no pain and 10 = the worst imaginable pain) measured at rest and during handling in subsequent medication.
Time frame: 6 hours
Proportion of participants who achieve at least 50% pain reduction
Assessment of the proportion of participants who achieve at least 50% pain reduction within 6 hours, through assessment of SPID (sum of the pain intensity difference) after the first dose of study drugs;
Time frame: 6 hours
Assessment of complete pain relief
Assessment of complete pain relief by verbal scale assessment of pain relief (VRS where 0 = no pain relief, 1 = mild pain relief, 2 = moderate pain relief, 3 = good pain relief, and 4 = excellent pain relief).
Time frame: 72 hours
Time to pain relief
Median time to pain relief
Time frame: During hospitalization
Assessment of satisfaction with treatment by the participant
Assessment of satisfaction with treatment by the participant using a standard categorical rating scale: Patient-reported global evaluation of Eficacy (PGE) scale of 5-points where 0=poor, 1=fair, 2=good , 3=very good, and 5=excellent response to therapy).
Time frame: 14 days
Presence of adverse events
Time frame: 14 days
Plan to share: Undecided — The data may be shared with other parties upon reasonable request to the corresponding author of the publications and after agreement with the sponsor.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Mar 2024, 11 months.
Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 11 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brazilian Clinical Research Institute